Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Clinical trial NCT06518551 · RECRUITING

Trial details

NCT number: NCT06518551
Sponsor: Omar Nadeem, MD
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Myeloma Multiple Myeloma Refractory Multiple Myeloma

Start date: 2024-11-01
Primary completion: 2029-12-31
Enrollment: 49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.